Unknown

Dataset Information

0

Feedforward loop between IMP1 and YAP/TAZ promotes tumorigenesis and malignant progression in glioblastoma.


ABSTRACT: YAP/TAZ have been identified as master regulators in malignant phenotypes of glioblastoma (GBM); however, YAP/TAZ transcriptional disruptor in GBM treatment remains ineffective. Whether post-transcriptional dysregulation of YAP/TAZ improves GBM outcome is currently unknown. Here, we report that insulin-like growth factor 2 (IGF2) mRNA-binding protein 1 (IGF2BP1 or IMP1) is upregulated in mesenchymal GBM compared with proneural GBM and correlates with worse patient outcome. Overexpression of IMP1 in proneural glioma stem-like cells (GSCs) promotes while IMP1 knockdown in mesenchymal GSCs attenuates tumorigenesis and mesenchymal signatures. IMP1 binds to and stabilizes m6A-YAP mRNA, leading to activation of YAP/TAZ signaling, depending on its m6A recognition and binding domain. On the other hand, TAZ functions as enhancer for IMP1 expression. Collectively, our data reveal a feedforward loop between IMP1 and YAP/TAZ maintaining GBM/GSC tumorigenesis and malignant progression and a promising molecular target in GBM.

SUBMITTER: Yang J 

PROVIDER: S-EPMC10154852 | biostudies-literature | 2023 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Feedforward loop between IMP1 and YAP/TAZ promotes tumorigenesis and malignant progression in glioblastoma.

Yang Jia J   Wu Xujia X   Wang Jia J   Guo Xing X   Chen Junju J   Yang Xuesong X   Zhong Jian J   Li Xixi X   Deng Zhong Z  

Cancer science 20230301 5


YAP/TAZ have been identified as master regulators in malignant phenotypes of glioblastoma (GBM); however, YAP/TAZ transcriptional disruptor in GBM treatment remains ineffective. Whether post-transcriptional dysregulation of YAP/TAZ improves GBM outcome is currently unknown. Here, we report that insulin-like growth factor 2 (IGF2) mRNA-binding protein 1 (IGF2BP1 or IMP1) is upregulated in mesenchymal GBM compared with proneural GBM and correlates with worse patient outcome. Overexpression of IMP1  ...[more]

Similar Datasets

| S-EPMC6724531 | biostudies-literature
| S-EPMC6115388 | biostudies-literature
| S-EPMC9929636 | biostudies-literature
| S-EPMC4559818 | biostudies-literature
| S-EPMC10710495 | biostudies-literature
| S-EPMC5938705 | biostudies-literature
| S-EPMC12861111 | biostudies-literature
| S-EPMC7871510 | biostudies-literature